WO2014077365A1 - 特定のラクトバチルス・ガセリ株又はその処理物を含有するストレス性腸障害の軽減剤 - Google Patents
特定のラクトバチルス・ガセリ株又はその処理物を含有するストレス性腸障害の軽減剤 Download PDFInfo
- Publication number
- WO2014077365A1 WO2014077365A1 PCT/JP2013/080930 JP2013080930W WO2014077365A1 WO 2014077365 A1 WO2014077365 A1 WO 2014077365A1 JP 2013080930 W JP2013080930 W JP 2013080930W WO 2014077365 A1 WO2014077365 A1 WO 2014077365A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- strain
- lactobacillus gasseri
- stress
- diarrhea
- lactic acid
- Prior art date
Links
- 241000186606 Lactobacillus gasseri Species 0.000 title claims abstract description 120
- 238000011282 treatment Methods 0.000 title claims abstract description 33
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 48
- 241001465754 Metazoa Species 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 239000004480 active ingredient Substances 0.000 claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 235000013373 food additive Nutrition 0.000 claims abstract description 14
- 239000002778 food additive Substances 0.000 claims abstract description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 132
- 206010012735 Diarrhoea Diseases 0.000 claims description 106
- 241000894006 Bacteria Species 0.000 claims description 88
- 239000004310 lactic acid Substances 0.000 claims description 66
- 235000014655 lactic acid Nutrition 0.000 claims description 66
- 230000028327 secretion Effects 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 230000000694 effects Effects 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 32
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 29
- 208000035475 disorder Diseases 0.000 claims description 28
- 230000000813 microbial effect Effects 0.000 claims description 28
- 230000009471 action Effects 0.000 claims description 24
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 22
- 230000001603 reducing effect Effects 0.000 claims description 21
- 230000001629 suppression Effects 0.000 claims description 20
- 230000002401 inhibitory effect Effects 0.000 claims description 17
- 235000015140 cultured milk Nutrition 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 16
- 239000000902 placebo Substances 0.000 claims description 16
- 229940068196 placebo Drugs 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 208000028774 intestinal disease Diseases 0.000 claims description 14
- 230000001734 parasympathetic effect Effects 0.000 claims description 14
- 235000013376 functional food Nutrition 0.000 claims description 13
- 108010062745 Chloride Channels Proteins 0.000 claims description 12
- 102000011045 Chloride Channels Human genes 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 11
- 230000008035 nerve activity Effects 0.000 claims description 9
- 235000019730 animal feed additive Nutrition 0.000 claims description 8
- 210000001072 colon Anatomy 0.000 claims description 8
- 230000000116 mitigating effect Effects 0.000 claims description 8
- 230000009467 reduction Effects 0.000 claims description 8
- 230000000968 intestinal effect Effects 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 241000186660 Lactobacillus Species 0.000 claims description 6
- 229940039696 lactobacillus Drugs 0.000 claims description 6
- 230000004083 survival effect Effects 0.000 claims description 6
- 239000000417 fungicide Substances 0.000 claims description 5
- 210000000936 intestine Anatomy 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 2
- 206010016803 Fluid overload Diseases 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 239000000654 additive Substances 0.000 abstract description 10
- 230000000996 additive effect Effects 0.000 abstract description 3
- 230000035882 stress Effects 0.000 description 101
- 210000004027 cell Anatomy 0.000 description 87
- 239000000047 product Substances 0.000 description 36
- 238000012360 testing method Methods 0.000 description 21
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 17
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 17
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- 239000002609 medium Substances 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 230000001954 sterilising effect Effects 0.000 description 14
- -1 glycerin fatty acid ester Chemical class 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000004659 sterilization and disinfection Methods 0.000 description 11
- 238000012258 culturing Methods 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 238000000855 fermentation Methods 0.000 description 9
- 230000004151 fermentation Effects 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 8
- 210000002429 large intestine Anatomy 0.000 description 8
- 208000004998 Abdominal Pain Diseases 0.000 description 7
- 101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000008991 intestinal motility Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 208000018522 Gastrointestinal disease Diseases 0.000 description 5
- 240000001046 Lactobacillus acidophilus Species 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 210000004921 distal colon Anatomy 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000037427 ion transport Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 240000006024 Lactobacillus plantarum Species 0.000 description 4
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 4
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 4
- 239000003899 bactericide agent Substances 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 229940072205 lactobacillus plantarum Drugs 0.000 description 4
- 230000007383 nerve stimulation Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000002438 stress hormone Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241000186605 Lactobacillus paracasei Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000008641 drought stress Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000020510 functional beverage Nutrition 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- YHQDZJICGQWFHK-UHFFFAOYSA-N 4-nitroquinoline N-oxide Chemical compound C1=CC=C2C([N+](=O)[O-])=CC=[N+]([O-])C2=C1 YHQDZJICGQWFHK-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GMGWMIJIGUYNAY-UHFFFAOYSA-N MeIQ Chemical compound CC1=CC2=NC=CC=C2C2=C1N(C)C(N)=N2 GMGWMIJIGUYNAY-UHFFFAOYSA-N 0.000 description 2
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229940124415 agent for irritable bowel syndrome Drugs 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000741 diarrhetic effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003871 intestinal function Effects 0.000 description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- NZRLNLVUUYPAGG-UHFFFAOYSA-N 1,4‐dimethyl‐2H‐pyrido[4,3‐b]indol‐3‐amine Chemical compound C1=CC=C2C3=C(C)NC(N)=C(C)C3=NC2=C1 NZRLNLVUUYPAGG-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 101150007969 ADORA1 gene Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 101150061984 Adcy5 gene Proteins 0.000 description 1
- 101710128948 Adenosine receptor A1 Proteins 0.000 description 1
- 102100033346 Adenosine receptor A1 Human genes 0.000 description 1
- 102100032161 Adenylate cyclase type 5 Human genes 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 102100033394 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- AANLCWYVVNBGEE-IDIVVRGQSA-L Disodium inosinate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 AANLCWYVVNBGEE-IDIVVRGQSA-L 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000490229 Eucephalus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AYLURHVFAYRSHT-UHFFFAOYSA-N Glu-P-1 Chemical compound C1=C(N)N=C2N3C=CC=C(C)C3=NC2=C1 AYLURHVFAYRSHT-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 101000775478 Homo sapiens Adenylate cyclase type 5 Proteins 0.000 description 1
- 101000732617 Homo sapiens Angiotensinogen Proteins 0.000 description 1
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000945751 Homo sapiens Leukocyte cell-derived chemotaxin-2 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 101150002416 Igf2 gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241001407640 Lactobacillus kefiranofaciens subsp. kefirgranum Species 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102100034762 Leukocyte cell-derived chemotaxin-2 Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241000031670 Saccharopolyspora thermophila Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 235000013890 disodium inosinate Nutrition 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002036 drum drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940004311 lactobacillus casei rhamnosus Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006402 liver broth Substances 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000001809 melena Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000020200 pasteurised milk Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000001967 plate count agar Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000470 submucous plexus Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000001040 synthetic pigment Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Definitions
- the present invention relates to a reducing agent (or inhibitor) of hypersecretion of water in the intestinal tract of a subject, which contains a live cell or bactericidal cell of a specific Lactobacillus gasseri strain or a processed product thereof as an active ingredient, or a stress property.
- the present invention relates to an agent for reducing (or suppressing) intestinal disorders, particularly stressful diarrhea symptoms.
- the present invention also relates to a novel low-temperature resistant Lactobacillus gasseri strain and a method for producing the same.
- the present invention further relates to a stress intestinal disorder alleviating agent (or inhibitor) comprising the low-temperature resistant Lactobacillus gasseri strain or a processed product thereof as an active ingredient.
- the present invention also relates to a food additive or animal feed additive, or a food or a pharmaceutical composition containing the above-described alleviating agent (or inhibitor).
- JP 2009-102292 A includes Lactobacillus paracasei subsp. Paracasei Lactobacillus paracasei subsp. Paracasei as an active ingredient, a cytokine production regulating action, A stress suppressor based on an infection-protecting action, fattening action or diarrhea-suppressing action is described.
- stress suppression refers to alleviating symptoms such as loss of appetite, indigestion, insomnia, poor physical condition, and infection by suppressing nonspecific reactions in the body caused by stressors, which are external stimuli that cause stress. It is stated that you can.
- JP 2009-100692 (Patent Document 2) and JP 2008-212140 (Patent Document 3) contain a lactobacillus microorganism having a stress-reducing action, and a lactic acid bacteria preparation for mammals It is described that, by administering a specific lactic acid bacterium to a mammal, it exhibits an excellent stress-reducing effect and can prevent and treat digestive diseases such as diarrhea caused by stress. .
- Patent Document 4 describes a pharmaceutical preparation necessary for the prevention and / or treatment of gastrointestinal disorders in humans and animals, which is Lactobacillus casei rhamnosus having the deposit number NCIMB 40564 ( A pharmaceutical preparation is described, characterized in that it comprises a viable microbial strain of Lactobacillus casei ⁇ ⁇ ⁇ ⁇ ⁇ rhamnosus) LB21 in at least one pharmaceutically acceptable carrier medium in which the microorganism maintains its viability .
- JP 2011-200211 A (Patent Document 5) describes an anti-ulcer agent containing Lactobacillus gasseri MCC1183 strain, which is used for the prevention or prevention of gastric ulcer or duodenal ulcer caused by Helicobacter pylori. It is described as being used for treatment.
- JP-T 2009-511471 discloses at least one probiotic bacterium selected from lactic acid bacteria for the production of a pharmaceutical composition for the treatment and / or prevention of autoimmune diseases.
- the use of (Probiotic bacteria) strains is described, and the autoimmunity may be multiple sclerosis (MS), allergy, psoriasis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, I Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, selected from the group consisting of organ-specific autoimmunity such as type 2 diabetes, inflammatory bowel disease, and systemic lupus erythematosus Rhamobasus (Lactobacillus rhamnosus), Lactobacillus fermentum (Lactobacillus fermentum), Lactobacillus paracasei, It is described as selected from the group consisting of finely Lactobac
- Patent Document 7 discloses an inflammatory bowel disease and / or irritable bowel comprising Lactobacillus gasseri SBT2055 (referred to as LG2055) (FERM P-15535) or its fermentation product as an active ingredient. Syndrome prophylaxis and treatment agents are described. In general, psychological stress control is performed for the treatment of irritable bowel syndrome, and stages ranging from intestinal and laxatives to antipsychotics are applied according to symptoms. It is described that a typical drug treatment is given.
- Non-patent Document 1 Daisuke Sawada et al., 13th Society of Intestinal Bacteriology (2009), Tokyo, Japan (Non-patent Document 1) improved the stress relieving action of Lactobacillus gasseri CP2305 strain by living cells, such as stress abdominal pain It is described.
- Patent Document 8 JP-A 2003-95963 (Patent Document 8) describes a preventive and therapeutic agent for inflammatory bowel disease or irritable bowel syndrome caused by Lactobacillus gasseri cells or fermentation products thereof.
- JP 2009-102292 JP 2009-100692 JP 2008-212140 A Japanese Patent No. 4350170 JP 2011-200211 Special table 2009-511471 Japanese Patent No.4853986 JP 2003-95963 A
- Lactobacillus gasseri strain a kind of lactic acid bacteria
- gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome.
- gastrointestinal disorders also have a description for estimating the relationship with stress.
- Lactobacillus gasseri strains significantly prevented, improved or treated gastrointestinal disorders, especially the effects of suppressing excessive water secretion and stress-related diarrhea, while suppressing excessive stress and maintaining normal intestinal motility normally.
- a lactic acid bacterium having an action of reducing stress-induced intestinal disorders (cold-resistant).
- Lactobacillus gasseri strains significantly improve stress diarrhea symptoms while maintaining excessive intestinal motility under conditions exposed to stress that secretes stress hormones in the brain. There is no description about this. In particular, there is no description regarding suppression (reduction or alleviation) of stress diarrhea due to stress load on healthy individuals who are distinguished from IBS patients.
- An object of the present invention is to prevent the production of a survivor or killed product of Lactobacillus gasseri or a processed product thereof from excessive secretion of water, or stress disorders associated with excessive secretion of water, such as stress diarrhea or stress abdominal pain. And to use for treatment.
- the present invention includes the following features.
- Lactobacillus gasseri CP2305s strain (NITE BP-1405), or Lactobacillus gasseri CP2305 strain (FERM BP-11331) or derivative strain derived from CP2305s strain (NITE BP-1405), treated cells thereof Or a mixture thereof as an active ingredient, an agent for alleviating hypersecretion of water in the intestinal tract, stress diarrhea, stress bowel disorder, irritable bowel syndrome, or inflammatory bowel disease.
- the derivative strain derived from the CP2305 strain, the CP2305s strain, or the Lactobacillus gasseri CP2305 strain (FERM BP-11331) or the CP2305s strain (NITE BP-1405) is a living cell or a fungicide, The alleviating agent according to 1) or (2).
- the alleviating agent according to any one of (1) to (7) which is an agent for improving drought stress diarrhea.
- a method for producing animal feed comprising the step of producing an animal feed by blending the mitigating agent according to any one of (1) to (8) with an animal feed ingredient.
- Lactobacillus gasseri CP2305 strain (FERM BP-11331), Lactobacillus gasseri CP2305s strain (NITE BP-1405), or Lactobacillus gasseri CP2305 strain (FERM BP-11331) or a derivative derived from CP2305s strain
- Viable or bactericidal cells of Lactobacillus gasseri CP2305s strain (NITE405BP-1405), or derived from Lactobacillus gasseri CP2305 strain (FERM BP-11331) or CP2305s strain, and their cells A food or drink containing a processed product or a mixture thereof.
- Viable or bactericidal cells of Lactobacillus gasseri CP2305s strain (NITE BP-1405), or derived from Lactobacillus gasseri CP2305 strain (FERM BP-11331) or CP2305s strain, and their cells
- Lactobacillus gasseri CP2305s strain (NITE BP-1405), or derived from Lactobacillus gasseri CP2305 strain (FERM BP-11331) or CP2305s strain, and their cells
- Prevention or reduction of intestinal hydration, stress diarrhea, stress bowel disorder, irritable bowel syndrome, or inflammatory bowel disease characterized by containing a processed product or a mixture thereof as an active ingredient Or a pharmaceutical composition for inhibition or treatment.
- Hypersecretion in the intestinal tract, stress diarrhea, stress comprising the alleviating agent according to any one of (1) to (8) and a pharmaceutically acceptable carrier, excipient or diluent.
- Lactic acid bacteria having an action to reduce stress intestinal disorders equivalent to or higher than that of Lactobacillus gasseri CP2305 strain (FERM ⁇ BP-11331) or Lactobacillus gasseri CP2305s strain (NITE BP-1405) and different from CP2305 strain.
- the stress-induced intestinal disorder reducing action is equivalent to Lactobacillus gasseri CP2305 strain (FERM BP-11331) or Lactobacillus gasseri CP2305s strain (NITE BP-1405) in the diarrhea score described in Example 3 described later
- the lactic acid bacterium according to (20) which has the above-described action for suppressing stress diarrhea.
- the above lactic acid bacteria are Lactobacillus gasseri CP2305s strain (NITENBP-1405), Lactobacillus gasseri CP2305 strain (FERM BP-11331) derivative or Lactobacillus gasseri CP2305s strain (NITE BP-1405) derivative strain
- the lactic acid bacterium according to any one of (20) to (26).
- Lactic acid bacteria For use in the prevention or alleviation of hypersecretion in the enema, stress diarrhea, stress bowel disorder, irritable bowel syndrome, diarrhea-type irritable bowel syndrome, or inflammatory bowel disease. ) Lactic acid bacteria according to any one of (27).
- Lactic acid bacteria consisting of Lactobacillus gasseri CP2305s strain (NITE-BP-1405), or Lactobacillus gasseri CP2305 strain (FERM-BP-11331) or a derivative derived from CP2305s strain.
- Lactic acid bacteria having a low temperature tolerance with a survival rate of 60% or more when kept on ice for 5 hours.
- the ⁇ diarrhea score described in Example 3 described later '' in (21) above is specifically a diarrhea score evaluated by the method described in Example 3 of the present specification.
- the i value is the measured stool weight (g)
- the ii value is a score determined from the stool score criteria shown in FIG. 5 (ie, score 1, normal stool; score 2, slightly diarrhea stool; Score 3, diarrheal stool that began to collapse; score 4, diarrheal stool without shape).
- Lactobacillus gasseri CP2305 strain (FERMFERBP-11331), Lactobacillus gasseri CP2305s strain (NITE BP-1405), or a strain derived from Lactobacillus gasseri CP2305 strain (FERM BP-11331) or CP2305s strain of the present invention
- Derived strains, treated products thereof, or a mixture thereof inhibits suppression of stress-induced pelvic (parasympathetic) nerve activity to maintain normal intestinal motility, and reduces stress diarrhea in subjects. It is effective for prevention, reduction or treatment of stress bowel disorder because of effective suppression.
- This figure shows the viability rate of the low-temperature resistant strains (CP2305s, AD) obtained by cold shocking the Lactobacillus gasseri CP2305 strain.
- This figure shows the influence of live cells, fungicides, and derived CP2305s fungicides of Lactobacillus gasseri CP2305 strain on the CRF-induced diarrhea model.
- Placebo is a negative control that does not contain the CP2305 strain.
- * Indicates that the risk factor p is less than 0.05.
- This figure shows changes in colon chloride channel-related gene expression after CRF induction. It shows that the chloride channel-related gene that increases after CRF administration in the placebo group is suppressed in the CP2305 strain administration group.
- Agt is angiotensinogen (serpin peptidase inhibitor, clade A, member 8)
- Adcy5 is adenylate cyclase 5
- Adora1 is Adenosine receptor A1
- Ngf is nerve growth factor (beta polypeptide)
- Igf2 is insulin-factor g2 Represents insulin-like growth factor 1.
- This figure shows the effect of CP2305 strain administration on the pelvic (parasympathetic) nerve.
- This figure shows a stool score criterion for calculating a diarrhea score in an experiment relating to the present invention.
- the stool score was evaluated on a scale of 1 to 4 according to the “water condition” and “shape” of the stool (the color of the stool is not subject to the stool score criteria, but to show the effect of the present invention) It is attached as reference information.)
- This figure shows the effect of administration of various lactic acid bacteria on the CRF-induced diarrhea model.
- Lactic acid bacteria are Lactobacillus gasseri strain CP2305 viable cells, known deposited strain A (L. gasseri) and commercially available live cell preparation B (including L. acidophilus). Placebo is a negative control that does not contain the CP2305 strain.
- This figure shows the effect of administration of sterilized fermented milk of various lactic acid bacteria on nerve stimulation-induced ion transport in the large intestine.
- the vertical axis indicates the value when the percentage of ion secretion is 100% of the placebo (negative control) ion secretion.
- A known deposited strain A (L. gasseri)
- B L. acidophilus
- C B. pseudocatenulatum
- D L. delbrueckii
- E S. thermophilus
- F L. kefirgranum.
- # Indicates that the risk factor p is less than 0.05.
- This figure shows the effects of administration of each CP2305 strain, known deposited strain A (L. gasseri) and L.
- the vertical axis indicates the value when the percentage of ion secretion is 100% of the placebo (negative control) ion secretion. * Indicates that the risk factor p is less than 0.05.
- This figure shows the effects of administration of viable cells and sterilized cells of CP2305 strain, viable fermented milk and sterilized fermented milk of CP2305 strain on ion transport in rat large intestine (distal colon).
- the vertical axis indicates the value when the percentage of ion secretion is 100% of the placebo (negative control) ion secretion.
- # Indicates that the risk factor p is less than 0.05.
- the present invention comprises, as an active ingredient, a living cell or sterilized body of Lactobacillus gasseri CP2305 strain (FERM BP-11331) (hereinafter also simply referred to as “CP2305 strain”), a treated product thereof, or a mixture thereof.
- CP2305 strain Lactobacillus gasseri CP2305 strain
- An inhibitor of hypersecretion of water in the intestinal tract of a subject is provided.
- the present invention also includes a Lactobacillus gasseri CP2305s strain (NITE BP-1405) (hereinafter also simply referred to as “CP2305s strain”), or a Lactobacillus gasseri CP2305 strain (FERM BP-11331) or a derivative derived from CP2305s strain.
- a strain eg, a low temperature resistant derivative is provided.
- the Lactobacillus gasseri strain is exposed to a temperature of 10 ° C. or lower, the surviving low-temperature resistant strain is selected and bred, this operation is repeated once or more as necessary, and the surviving low-temperature resistant strain is recovered.
- a low-temperature resistant strain can be produced.
- a cold-resistant strain having a viable cell rate of about 60% or more, preferably about 70% or more, more preferably about 80% or more, 85% or more, 90% or more after cold shock can be obtained. .
- Lactobacillus gasseri CP2305s strain (NITENBP-1405) could be obtained (FIG. 1).
- the Lactobacillus gasseri CP2305s strain was obtained by the applicant from the Japan Institute for Product Evaluation and Technology Patent Microorganisms Depositary Center (Kazusakami, Kisarazu City, Chiba Prefecture 292-0818, Japan), an international depositary organization based on the provisions of the Budapest Treaty. Foot 2-5-8) has been deposited internationally as NITE BP-1405 on August 14, 2012.
- the present invention is further derived from Lactobacillus gasseri CP2305 strain (FERM BP-11331), Lactobacillus gasseri CP2305s strain (NITE BP-1405), Lactobacillus gasseri CP2305 strain (FERM BP-11331) or CP2305s strain Strains (for example, low-temperature resistant derivatives), treated products thereof, or mixtures thereof as active ingredients, hypersecretion in the intestinal tract, stress diarrhea, stress intestinal disorders, irritability Provided is a relieving agent for irritable bowel syndrome, diarrhea-type irritable bowel syndrome or inflammatory bowel disease.
- the CP2305 strain, the CP2305s strain, or a derivative strain (for example, a low temperature resistant derivative strain) from the CP2305 strain or the CP2305s strain may be either a living cell or a sterilized cell.
- the “subject” in this specification refers to animals belonging to mammals and birds, preferably primates such as humans, domestic animals such as cows, horses, sheep, goats, pigs, chickens, and turkeys, and competition animals such as horses. , Pets such as dogs and cats.
- the other strains derived from the CP2305 strain or the CP2305s strain also have an effect of reducing stress intestinal disorder that is equal to or higher than that of the parent strain, and an action of suppressing excessive secretion of water in the intestine. It can be obtained as a lactic acid bacterium belonging to Lactobacillus gasseri species different from the above strain.
- Such derivative strains include irradiating the parent strain with ultraviolet light, culturing the parent strain in the presence of a mutagenic substance, culturing at a temperature other than the optimum temperature, culturing in the presence of an organic solvent, etc.
- mutagenic substances include 3-amino-1,4-dimethyl-5H-pyrido [4,3-b] indole (Trp-P-1), 2-amino-6-methylimida-5H-pyrido [1 , 2-a-3 ', 2'-d] -imidazole (Glu-P-1), 2-amino-3,4-dimethylimidazo [4,5-f] quinoline (MeIQ), 4-nitroquinoline- N-oxide (4NQO), N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) and the like can be mentioned.
- the target derivative has, for example, (1) Lactobacillus gasseri CP2305 strain (FERM BP-11331) or Lactobacillus gasseri CP2305s strain (NITE BP-1405) equivalent to or better than the stress intestinal disorder
- the stress intestinal disorder reducing action has a diarrhea score that is equivalent to or higher than that of the above strain, and (2) the survival rate when kept on ice for 5 hours or more is 60% or more, (3) Selection can be made using as an indicator that it has an action of inhibiting the suppression of pelvic (parasympathetic) nerve activity due to stress, and (4) an action of inhibiting water secretion by inhibiting the colonic chloride channel.
- the present invention also relates to a lactic acid bacterium having such characteristics (1) and any of the characteristics (2) to (4).
- Lactobacillus gasseri SBT 2055 strain (FERM P-15535) having a preventive / therapeutic effect on inflammatory bowel disease or irritable bowel syndrome is known (JP 2003-95963 A). Issue gazette).
- This bacterium is a lactic acid bacterium isolated and cultured from the Japanese intestine. In a test using live bacteria using the DDS-induced ulcerative colitis model, it was reported that blood stool and melena were suppressed compared to the control group. ing.
- Lactobacillus gasseri OLL2716 strain (FERM BP-6999) that improves the gut microbiota and reduces the occurrence of diarrhea (Japanese Patent Laid-Open No. 2004-305128).
- Japanese Patent Laid-Open No. 2004-305128 Japanese Patent Laid-Open No. 2004-305128
- the incidence of diarrhea rate of occurrence of diarrhea within 2 weeks after introduction into the test ranch
- these known Lactobacillus gasseri strains are clearly different from the CP2305 strain and the CP2305s strain that is a low-temperature resistant derivative thereof.
- CP2305s strain which is a low temperature resistant strain of CP2305 strain, or a viable cell and a sterilized cell of CP2305 strain or a derivative strain from CP2305s strain (for example, a low temperature resistant derivative strain), Surprisingly, it has the effect of suppressing excessive secretion of water from the intestinal tract, and has the effect of significantly suppressing stress diarrhea (see FIGS. 1 and 2).
- This action is achieved by sterilizing fermented milk of the parent strain Lactobacillus gasseri CP2305 with known deposited Lactobacillus gasseri strains, L. acidophilus, B. pseudocatenulatum, L. ophil delbrueckii, S.
- Lactobacillus gasseri CP2305 strain of the present invention Lactobacillus gasseri CP2305s strain, or a derivative strain such as a low temperature resistant derivative strain from CP2305 strain or CP2305s strain, using a medium usually used for culture of lactic acid bacteria, suitable It can be prepared by culturing under conditions. As long as the medium used for culture contains a carbon source, a nitrogen source, inorganic salts, and the like and can culture lactic acid bacteria efficiently, either a natural medium or a synthetic medium may be used. If so, a known medium suitable for the strain to be used can be appropriately selected.
- the carbon source lactose, glucose, sucrose, fructose, galactose, molasses, etc.
- organic nitrogen-containing materials such as casein hydrolyzate, whey protein hydrolyzate, and soy protein hydrolyzate can be used.
- inorganic salts phosphates, sodium, potassium, magnesium and the like can be used.
- the medium suitable for culturing lactic acid bacteria include MRS liquid medium, GAM medium, BL medium, Briggs LiverBroth, animal milk, skim milk, and milky whey.
- a sterilized MRS medium can be used.
- the culture of the CP2305s strain of the present invention, or a derivative strain such as a low temperature resistant derivative from the CP2305 strain or the CP2305s strain is 20 ° C. to 50 ° C., preferably 25 ° C. to 42 ° C., more preferably about 37 ° C.
- the temperature condition can be adjusted by a thermostatic bath, a mantle heater, a jacket, or the like.
- the anaerobic condition means a hypoxic environment where bacteria can grow, for example, by using an anaerobic chamber, an anaerobic box, a sealed container or bag containing an oxygen scavenger, or the like.
- Anaerobic conditions can be achieved by simply sealing the culture vessel.
- the culture may be any culture mode such as stationary culture, shaking culture, tank culture and the like.
- the culture time can be 3 hours to 100 hours or more, preferably about 10 hours to 50 hours.
- the pH of the medium at the start of culture is preferably maintained at 3.5 to 8.0.
- viable cell bodies separated from the culture solution by a separation technique such as filtration or centrifugation, or a viable cell-containing culture solution can be obtained.
- a sterilized body can be obtained by subjecting these live cells or a culture solution thereof to a known sterilization treatment using an autoclave or the like.
- a microbial cell processed material can be produced from a living microbial cell or a living microbial cell culture solution, and can be subjected to a sterilization treatment as necessary.
- the treated microbial cell product is obtained by subjecting the microbial cell to physical, chemical, biological treatment such as drying treatment, destruction or crushing treatment, and fermentation treatment. Therefore, examples of the processed microbial cell product used in the present invention include dried microbial cells, disrupted microbial cells, crushed microbial cells, fermented processed products (for example, fermented milk), and the like.
- the dried microbial cells can be obtained by subjecting the microbial cells isolated from the culture solution to a sterilizing treatment if necessary, and subjecting the microbial cells to a drying treatment.
- a drying treatment examples include drum drying, spray drying, vacuum drying, freeze drying, and the like.
- Destructed cells or broken cells can be obtained by treating cells by crushing, grinding, enzyme treatment, chemical treatment, dissolution, or the like.
- the disrupted or disrupted cells consist essentially of all the solid and soluble components of the disrupted or disrupted cells, and can be obtained, for example, by subjecting the disrupted or disrupted product to lyophilization as it is.
- Destruction or crushing can be performed by a known method such as physical crushing, enzyme dissolution treatment, chemical treatment, and the like. Physical crushing may be carried out either wet or dry, with stirring using a homogenizer, ball mill, bead mill, dyno mill, planetary mill, etc., using a jet mill, French press, cell crusher, etc. Can do.
- the enzyme dissolution treatment can be performed by destroying the cell structure of the fungus using an enzyme such as lysozyme.
- the chemical treatment can be carried out by destroying the cell structure of the fungus using a surfactant such as glycerin fatty acid ester and soybean phospholipid. Preferably, physical crushing.
- a specific method for preparing a crushed material is, for example, a known dynomill cell crusher (DYNO-MILL crusher (Shinmaru Enterprises (Japan, Osaka, Japan), etc.)) , Using glass beads, crushing tank temperature 10-30 ° C at peripheral speed 10.0-20.0m / s (eg about 14.0m / s), processing flow rate 0.1-10L / 10min (eg about 1L / 10min) This includes crushing the cells by treating 1 to 7 times (for example, 3 to 5 times) (for example, about 15 ° C.).
- the suspension of the bacteria is discharged in a known wet jet mill cell crusher (JN20 Nanojet Pal (Joko (Japan, Kanagawa, Kawasaki), etc.)) with a discharge pressure of 50 to 1000 MPa (for example, 270 MPa) and a processing flow rate.
- the cells can be crushed by treating 1 to 30 times (for example, 10 times) at 50 to 1000 (for example, 300 ml / min).
- a known dry planetary mill cell crusher the cell powder is mixed with various balls (for example, zirconia 10 mm balls, zirconia 5 mm balls, alumina 1 mm balls) at a rotational speed of 50 to 10,000 rpm (for example, 240 rpm, 190 rpm).
- Fermented milk can be obtained by inoculating a raw milk, skim milk powder or soy milk with a strain and performing fermentation under lactic acid bacteria fermentation conditions.
- the obtained fermentation product may be subjected to treatments such as filtration, dilution, and concentration as necessary.
- the above microbial cells and processed microbial cells can be used as they are or can be sterilized by sterilization.
- the sterilization treatment includes, for example, known treatments such as sterilization by high energy ray irradiation, heat sterilization, pressure sterilization, and autoclave sterilization.
- a preferred sterilization method is autoclave sterilization. This method comprises sterilizing a living bacterium or a bacterium-containing culture liquid in an autoclave (high-pressure steam sterilizer), for example, at a temperature of, for example, 110 ° C. to 140 ° C. under pressurized steam for about 10 minutes to 1 hour. Including.
- the CP2305 strain, CP2305s strain of the present invention, or a derivative strain such as a low-temperature resistant derivative from the CP2305 strain or the CP2305s strain, or a treated product thereof is described below. It is useful as an alleviating agent for excessive secretion, stress bowel disorder, stress diarrhea, irritable bowel syndrome, diarrhea-type irritable syndrome, or inflammatory bowel disease.
- stress diarrhea is a symptom accompanied by excessive secretion of water in the intestinal tract due to stress that causes stress hormones in the brain to be secreted. May not accompany.
- stressed abdominal pain means abdominal pain that occurs in the intestinal tract caused by stress, that is, exposed to stress that causes secretion of stress hormones in the brain.
- stressed diarrhea and “stressed abdominal pain” are distinguished from patients with irritable bowel syndrome (IBS) in that they are stressful symptoms caused by stress on healthy individuals .
- IBS irritable bowel syndrome
- stress diarrhea and “stress abdominal pain” are collectively referred to as “stressed bowel disorder”.
- “diarrhea symptoms of stress-induced intestinal disorder” means symptoms of stress diarrhea.
- intestinal hyperhydric secretion means excessive hypersecretion in the intestinal tract regardless of whether it is caused by stress or not.
- irritable bowel syndrome refers to irritable bowel syndrome.
- diarrhea-type irritable bowel syndrome is caused by a hypersensitive reaction when passing through the intestinal contents due to hypersensitivity of the large intestine, causing excessive contraction movements that promote drainage, frequent diarrhea symptoms, and chronic abdominal pain.
- Suffering from continuous anxiety due to stress increase the incidence of mental illness.
- the diagnostic criteria are defined in Rome III and are patients with low QOL regardless of the presence or absence of stress environment.
- inflammatory bowel disease is a general term for chronic diseases that cause inflammation of unknown cause mainly in the digestive tract, and mainly consists of two diseases, ulcerative colitis and Crohn's disease. Aggravated by stress, with diarrhea.
- the mitigating agent (or inhibitor) of the present invention is a CP2305 strain, a CP2305s strain, or a derivative strain such as a low-temperature resistant derivative strain from CP2305 strain or CP2305s strain, a treated product thereof, or an active ingredient comprising a mixture thereof, although not limited to the following, it contains, for example, about 0.1 wt% to 100 wt%, preferably about 10 wt% to about 90 wt% per mitigating agent.
- the above-mentioned alleviating agent can contain an excipient, a diluent or a carrier, and other additives as required, in addition to the above active ingredient.
- the form may be either a solid form or a liquid form.
- a solid form consists of arbitrary shapes, such as a powder, a granule, a tablet, a pellet, for example.
- the liquid form is, for example, a shape such as a suspension, an emulsion, a fermented liquid (for example, fermented milk).
- Excipients, diluents or carriers are substances that can usually be used in foods, animal feeds or pharmaceuticals as described below.
- Other additives are not necessarily required, but when added, examples include preservatives, pH adjusters, emulsifiers, antioxidants, and colorants as described below.
- the present invention further relates to a derivative strain such as the above-mentioned Lactobacillus gasseri CP2305 strain (FERM BP-11331), Lactobacillus gasseri CP2305s strain (NITE BP-1405), or a cold-tolerant derivative from CP2305 strain or CP2305s strain,
- a food additive or animal feed additive containing the above-mentioned alleviating agent (or inhibitor) is provided.
- the above alleviating agent or inhibitor
- These food additives or animal feed additives may be in solid or liquid form.
- the solid form consists of any shape such as powder, granule, tablet, pellet, gel, capsule and the like.
- the liquid form is, for example, a shape such as a suspension, an emulsion, a fermented liquid (for example, fermented milk).
- Excipients, diluents or carriers are substances that can normally be used in food or animal feed, and other additives include, for example, preservatives, pH adjusters, emulsifiers, colorants, nutritional supplements (natural or Artificial) sweeteners, seasonings, flavors and the like.
- the food additive or animal feed additive contains the above-mentioned mitigating agent, but is not limited to the following, but contains, for example, about 1 wt% to about 50 wt%, preferably about 5 wt% to about 20 wt% per additive. can do.
- a food additive or animal feed additive is added to food or animal feed to reduce excess intestinal hydration, stress diarrhea, stress bowel disorder, irritable bowel syndrome or inflammatory bowel disease Can be used to reduce excess intestinal hydration, stress diarrhea, stress bowel disorder, irritable bowel syndrome or inflammatory bowel disease Can be used to reduce excess intestinal hydration, stress diarrhea, stress bowel disorder, irritable bowel syndrome or inflammatory bowel disease Can be used to reduce excess intestinal hydration, stress diarrhea, stress bowel disorder, irritable bowel syndrome or inflammatory bowel disease Can be used to
- the present invention further includes an animal feed containing the above-mentioned alleviating agent (or inhibitor), or the above-described alleviating agent (or inhibitor) combined with an animal feed component, and the subject is subject to excessive water secretion and stress in the intestinal tract of the subject.
- a method for producing an animal feed comprising producing an animal feed having an effect of reducing diarrhea, stress bowel disorder, irritable bowel syndrome or inflammatory bowel disease is provided.
- an animal feed can be produced by blending an effective amount of the mitigation agent of the present invention with a feed component for producing an animal feed and formulating it into an arbitrary dosage form if necessary.
- the present invention further includes a derivative strain such as the aforementioned Lactobacillus gasseri CP2305 strain (FERMFERBP-11331), Lactobacillus gasseri CP2305s strain (NITE BP-1405), or a low temperature resistant derivative from CP2305 strain or CP2305s strain, Or a sterilized product thereof, a processed product thereof, or a mixture thereof, a food or drink containing the above-mentioned alleviating agent, a functional food or drink, or a food carrier or excipient containing the above-mentioned reducing agent.
- a derivative strain such as the aforementioned Lactobacillus gasseri CP2305 strain (FERMFERBP-11331), Lactobacillus gasseri CP2305s strain (NITE BP-1405), or a low temperature resistant derivative from CP2305 strain or CP2305s strain, Or a sterilized product thereof, a processed product thereof, or a mixture thereof, a food or
- the amount of the above-mentioned alleviating agent is determined depending on the form of the feed and foods and drinks and the desired effect (that is, suppressing excessive secretion of water in the intestinal tract of the subject, It can be determined appropriately by those skilled in the art in view of (suppressing diarrhea and the like).
- the total amount of sterilized or viable cells and / or treated cells of CP2305 strain, CP2305s strain, or a derivative strain such as a low temperature resistant derivative from CP2305 strain or CP2305s strain in animal feed or functional food and drink is 10 5 to 10 14 cfu / g, preferably 10 6 to about 10 13 cfu / g, more preferably 10 7 to 10 12 cfu / g.
- the amount of the bacterium is, for example, 0.001 to 10% by weight, preferably 0.01 to 5% by weight.
- the effective amount can be appropriately set by those skilled in the art based on the relationship between the added amount and the effect of reducing diarrhea symptoms.
- the animal feed dosage form has an arbitrary shape such as a powder, a granule, a tablet and a pellet in the case of a solid form, and has a shape such as a suspension and fermented milk in the case of a liquid form.
- the functional food dosage form may be of any shape such as powder, granule, tablet, pellet, gel, capsule, etc. in the solid form, and in the liquid form, such as suspension, emulsion, fermentation, etc.
- the shape is milk.
- tablets, pellets and capsules can be coated in a single layer or multiple layers with an enteric substance so as to be enteric.
- Enteric substances are those that do not dissolve at pH in the acidic range such as gastric juice but dissolve at pH in the neutral range, such as hypromellose phthalate, shellac, zein, lactoferrin, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose. Examples thereof include acetate succinate, carboxymethyl ethyl cellulose, and cellulose acetate phthalate.
- Excipients, diluents or carriers are not limited to the following: water, milk fermentation liquid, carbonated water, ethanol, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium alginate, water-soluble dextran, water-soluble dextrin, Examples include sodium carboxymethyl starch, carboxymethyl cellulose, starch, pectin, xanthan gum, gum arabic, casein, gelatin, agar, glycerin, propylene glycol, polyethylene glycol, petroleum jelly, paraffin, stearyl alcohol, mannitol, sorbitol, and lactose.
- Additives are not limited to the following, but are coloring agents (plant pigments, synthetic pigments, etc.), flavoring agents (natural flavoring agents, etc.), sweeteners (stevia, aster palm, etc.), preservatives (sodium acetate, Sorbic acid, etc.), emulsifiers (sodium chondroitin sulfate, propylene glycol fatty acid ester, etc.), antioxidants (disodium EDTA, vitamin C, etc.), pH adjusters (citric acid, etc.), chemical seasonings (sodium inosinate, sodium glutamate) Etc.), thickeners (xanthan gum, etc.), swelling agents (calcium carbonate, etc.), antifoaming agents (calcium phosphate), binders (sodium polyphosphate, etc.), nutrient enhancers (calcium fortifier, vitamin A, etc.
- the present invention further includes Lactobacillus gasseri CP2305 strain (FERM BP-11331), Lactobacillus gasseri CP2305s strain (NITE BP-1405), or a derivative strain such as CP2305 strain or CP2305 strain or CP2305s strain or a low temperature resistant derivative
- a medicinal product for preventing, reducing or suppressing or treating stress intestinal disorders characterized by containing, as an active ingredient, viable cells or bactericides, or processed products of these, or a mixture thereof A composition is provided.
- the present invention provides a subject with stress bowel disorders, particularly hypersecretion of water and stress, comprising the above-mentioned alleviating agent (or inhibitor) and a pharmaceutically acceptable carrier, excipient or diluent.
- a pharmaceutical composition for preventing, reducing or suppressing or treating diarrhea comprising the above-mentioned alleviating agent (or inhibitor) and a pharmaceutically acceptable carrier, excipient or diluent.
- the active ingredient of the present invention has an effect of suppressing stress bowel disorder, particularly excessive water secretion and stress diarrhea.
- CP2305 strain, CP2305s strain, or CP2305 strain, or a derivative strain such as a low-temperature resistant derivative from CP2305 strain or CP2305s strain (viable cells or sterilized cells), or a treated product thereof, as described above induces stress.
- has the effect of inhibiting pelvic (parasympathetic) nerve suppression that is, it has the function of maintaining intestinal motility normally by anti-stress, and the action of inhibiting colonic chloride channels, thereby suppressing excessive secretion of water in the intestinal tract
- Stress leads to stress-sensitive bowel disorders and exacerbates the symptoms of the disorder.
- CP2305 strain of the present invention CP2305s strain, or a derivative strain such as a low-temperature resistant derivative strain from CP2305 strain or CP2305s strain, In particular, it is effective for preventing, reducing or suppressing stress bowel disorder, or treating it, in order to suppress frequent diarrhea symptoms of stress bowel disorder. This effect was confirmed to be higher than any commercially available Lactobacillus gasseri strain preparation.
- the pharmaceutical composition can be formulated into any dosage form as long as it exhibits the above effects.
- examples thereof include tablets, capsules, granules, powders, powders, syrups, dry syrups, solutions, suspensions, emulsions, fermentation emulsions, and the like, and oral preparations, suppositories, etc. are particularly preferred.
- compositions As the active ingredient of the present invention, pharmaceutically acceptable commonly used excipients, carriers, diluents, disintegrants, binders, wetting agents, stabilizers, buffers, lubricants, preservatives, surfactants Additives such as sweeteners, flavoring agents, fragrances, acidulants, and coloring agents can be blended according to the dosage form, and can be produced according to conventional methods. Examples of these substances are those mentioned above.
- the total amount of the above-described CP2305 strain, CP2305s strain, or a derivative strain such as a low-temperature resistant derivative strain from CP2305 strain or CP2305s strain, and / or a cell-treated product in the pharmaceutical composition is not limited to the following.
- the amount of viable bacteria is 10 5 to 10 12 cfu / g, preferably 10 6 to about 10 12 cfu / g, more preferably 10 7 to 10 12 cfu / g, or
- the amount of the bacteria is, for example, 0.001 to 10% by weight, preferably 0.01 to 5% by weight.
- the effective amount can be appropriately set by those skilled in the art based on the relationship between the added amount and the effect of reducing diarrhea symptoms.
- the preferred administration method is oral administration or suppository administration.
- the pharmaceutical composition of the present invention is effective in preventing, reducing or treating hypersecretion of water in the intestinal tract, stressful bowel disorder, irritable bowel syndrome or inflammatory bowel disease, worsening of diarrhea symptoms during stress. is there.
- Example 1 ⁇ Breeding low temperature resistant strain> Inoculated with broth 10ml entering the test tube polypropylene-made capacity 15ml inner diameter 15 mm (food ⁇ land) Lactobacillus gasseri CP2305 strain (Number 10 3 to 10 4 bacteria), 37 ° C., 19 hours Culture was performed.
- a 15-ml test tube made of polypropylene having an inner diameter of 15 mm was inserted into a sufficient amount of ice above the liquid level in the test tube (on ice) and rapidly cooled and held for 5 hours. This culture and cooling were repeated 80 times to breed a strain having high low temperature tolerance.
- on ice means that 10 ml of the culture solution is put into a 15 ml test tube made of polypropylene with an inner diameter of 15 mm, and the test tube is inserted into a sufficient amount of ice above the liquid level in the test tube. The state of cooling.
- composition of the “food medium” used in the present specification is as follows (Table 1).
- ⁇ Evaluation of low temperature resistant strain The evaluation of the viability of the low temperature resistant strain in the evaluation of the low temperature resistant strain of the present invention was evaluated by the viable cell ratio before and after low temperature exposure (also referred to as “viability” in the present specification) as in the following formula. . Specifically, to inoculate evaluated strain broth 10ml entering the test tube polypropylene-made capacity 15ml of (bacterial number 10 3 to 10 4) the inner diameter of 15 mm (food ⁇ land), 37 ° C., Culture was performed for 19 hours.
- test tube After culturing for 19 hours, insert a test tube of 15 ml in diameter and made of polypropylene with a capacity of 15 ml into a sufficient amount of ice above the liquid level in the test tube and quickly cool it (on ice). After maintaining for 5 hours on ice, compare the number of viable bacteria before rapid cooling (before low temperature exposure) and the number of viable bacteria after holding for 5 hours on ice (after low temperature exposure) to evaluate the viable cell rate using the following formula.
- the viable cell rate is at least 60% or more, preferably 65% or more, more preferably 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more (see below) Strains exhibiting the formula are preferred.
- Viable bacteria rate (%) number of viable bacteria after low temperature exposure / number of viable bacteria before low temperature exposure x 100 The method for counting the number of viable bacteria was evaluated by measuring the viable count by counting the number of colonies after smearing the culture solution on an MRS agar medium or BCP-added plate count agar medium and culturing at 37 ° C. under slight aerobic condition. .
- Example 2 ⁇ Method for producing low temperature resistant strain>
- the target strain is cultured in a culture solution (e.g., a supplemented medium) at an appropriate culture temperature (e.g., about 37 ° C) and a moderate culture time (e.g., about 19 hours).
- a culture solution e.g., a supplemented medium
- the culture solution is kept at a temperature of 10 ° C. or lower, preferably 7 ° C. or lower, more preferably 5 ° C. or lower, more preferably 3 ° C.
- the strain that is resistant to low temperature which is the target temperature, is produced by exposure and, if necessary, repeating these cultivation and low temperature exposure.
- test cell combination diet is free for 3 weeks as follows: Ingested.
- Bacteria consumption in this study was estimated to be approximately 2.0 ⁇ 10 10 cells / day.
- CRF Corticotropin Releasing Factor
- the definition of diarrhea score is as follows.
- the stool collected at each time is quantified as the stool score of each time according to the stool score criteria shown in FIG. 5 from the water status and shape of the stool (the stool score (ii value) of each time)
- (d) Obtain the stool weight (i value) x stool score (ii value) each time.
- Lactobacillus gasseri CP2305s strain significantly suppressed stress diarrhea compared with placebo (CRF-1 only) (FIG. 2).
- the diarrhea inhibitory effect is equivalent to that of CP2305 strain (live cells and bactericides).
- Example 3 From the results of Example 3 above, it was proved that lactic acid bacteria having diarrhea scores of Example 3 of 11 or less were obtained.
- the diarrhea score is preferably 10 or less, more preferably 9 or less.
- lactic acid bacteria having a diarrhea score with a reduction rate of diarrhea score with respect to placebo of 90% or less can be obtained.
- Example 5 The result of the deposited bacterial strain A (L. gassei) as a comparison target is the result of administration of the same number of bacteria as the CP2305 strain. Moreover, the result of the commercially available live bacterial preparation B (L. acidphilus) is the result of administration so that the weight of the daily intake for humans is equivalent to the weight per unit body weight in terms of the body weight of the rat (FIG. 6). From these results, it has been proved that CP2305 strain has the effect of suppressing stress-related diarrhea from the commercially available bacterial agents that have been reported to have anti-diarrhea activity, and the CP2305s strain has the same effect as the CP2305 strain. This proved the superiority of the CP2305s strain.
- Example 6 Furthermore, dissection was performed 4 hours after administration of CRF, and colon tissues were extracted with total RNA using ISOGEN (Nippon Gene) and RNeasy Mini Kit (Qiagen, USA), and then gene expression was determined using Rat whole genome ver. 3 (G4847B, Agilent , USA). As a result, it was confirmed that the chloride channel-related gene increased after CRF administration in the placebo group was suppressed in the CP2305 strain administration group (FIG. 3). Therefore, the CP2305 strain is thought to suppress chloride channels and control water movement, and the CP2305s strain, which has the same diarrhea inhibitory effect, also suppresses chloride channels and controls water movement. Conceivable.
- Example 7 SD male rats (4 weeks old, manufactured by Kiwa Animal Co., Ltd.) are bred for 12 weeks under a light / dark cycle (lights on for 12 hours from 8 o'clock) for 1 week, and then CP2305 mixed diet or uncontained control powder diet for 3 weeks Ad libitum. On the day of the experiment, rats were fasted for 3 hours, then anesthetized with urethane, a cannula for intravenous administration was inserted into the jugular vein, and then the pelvic (parasympathetic) nerve that innervates the lower colon was lifted with a silver electrode, and its electrical activity was measured.
- Example 8 SD rat (weight: 380-400g, manufactured by Japan SLC) was anesthetized, decapitated and exsanguinated, distal to the distal colon according to anatomical criteria, and the rotatory and longitudinal muscle layers were examined under a microscope. After exfoliation, a mucosa-submucosa plexus specimen containing the submucosal plexus was prepared. The specimen was mounted in a Ussing chamber (CHM2, WPI, FL, USA) having a measurement area of 0.64 cm 2 , and a potential difference generated between the mucosa side and the serosa side of the specimen and a short-circuit current (I SC ) were measured.
- CHM2, WPI, FL, USA Ussing chamber having a measurement area of 0.64 cm 2
- a 10 mV command pulse was applied to the tissue for 3 seconds per minute, and the membrane conductance (Gt) was calculated from the amount of change in the short-circuit current.
- electrical stimulation 25 V, duration of 0.5 ms, 5 Hz, 120 s
- a test lactic acid bacterium or a diluted solution of fermented milk 500 ⁇ g / ml is administered to the mucous membrane side, changes in I SC and Gt are measured, and a test for Cl ⁇ / HCO 3 ⁇ secretion generated by neural stimulation induction The effect of the substance was evaluated.
- the sterilized fermented milk of CP2305 strain suppressed ion secretion more strongly than known deposited strain A (L. gasseri) and other 5 strains (BF), It was suggested that it regulates secretion and contributes to diarrhea suppression (Fig. 7).
- Example 9 Furthermore, in order to evaluate the effect of bacterial cells alone on nerve stimulation-induced ion transport in the rat large intestine (distal colon), sterilized lactic acid bacteria were prepared and administered. Compared with strain A (L. gasseri) and L. acidophilus germicide, it was suggested that ion secretion was significantly suppressed and strongly contributed to diarrhea suppression (FIG. 8).
- Lactobacillus gasseri CP2305 strain (FERM BP-11331), Lactobacillus gaselli CP2305s strain (NITE BP-1405) of the present invention, or a strain derived from CP2305 strain or CP2305s strain (for example, a low temperature resistant derivative strain)
- the treatment, or a mixture thereof inhibits the suppression of stress-induced pelvic (parasympathetic) nerve activity to maintain normal intestinal motility. It can be suppressed, reduced or improved.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Physiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nutrition Science (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Animal Husbandry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Fodder In General (AREA)
Abstract
Description
本発明は、ラクトバチルス・ガセリCP2305株(FERM BP-11331)(以下、単に「CP2305株」とも称する。)の生菌体若しくは殺菌体、その菌体処理物、或いはその混合物、を有効成分として含有することを特徴とする、被験体の腸管での水分過剰分泌の抑制剤を提供する。
本発明はまた、ラクトバチルス・ガセリCP2305s株(NITE BP-1405)(以下、単に「CP2305s株」とも称する。)、又はラクトバチルス・ガセリCP2305株(FERM BP-11331)もしくはCP2305s株から派生した派生株(例えば低温耐性派生株)、を提供する。
本発明はさらに、ラクトバチルス・ガセリCP2305株(FERM BP-11331)、ラクトバチルス・ガセリCP2305s株(NITE BP-1405)又はラクトバチルス・ガセリCP2305株(FERM BP-11331)若しくはCP2305s株から派生した派生株(例えば低温耐性派生株)、それらの菌体処理物、或いはそれらの混合物、を有効成分として含有することを特徴とする、腸管での水分過剰分泌、ストレス性下痢、ストレス性腸障害、過敏性腸症候群、下痢型過敏性腸症候群又は、炎症性腸疾患の軽減剤を提供する。
本発明はさらに、上記のラクトバチルス・ガセリCP2305株(FERM BP-11331)、ラクトバチルス・ガセリCP2305s株(NITE BP-1405)、又はCP2305株もしくはCP2305s株からの低温耐性派生株などの派生株、の生菌体又は殺菌体、それらの菌体処理物、或いはそれらの混合物、或いは、上記軽減剤(若しくは抑制剤)を含有する食品添加剤又は動物飼料添加剤を提供する。
本発明はさらに、ラクトバチルス・ガセリCP2305株(FERM BP-11331)、ラクトバチルス・ガセリCP2305s株(NITE BP-1405)、又はCP2305株又はCP2305株もしくはCP2305s株からの低温耐性派生株などの派生株、の生菌体又は殺菌体、それらの菌体処理物、或いはそれらの混合物、を有効成分として含有することを特徴とする、ストレス性腸障害を予防、軽減若しくは抑制、又は治療するための医薬組成物を提供する。
<低温耐性株の育種>
内径15mmのpolypropylene製の容量15mlの試験管に入った10mlの培養液(食添培地)にラクトバチルス・ガセリCP2305株(菌数103個~104個)を接種し、37℃、19時間培養を行った。
本発明の低温耐性株の評価における上記低温耐性株の生存性の評価を、下記の式のように、低温曝露前後の生菌率(本明細書において「生存率」ともいう。)で評価した。具体的には、評価対象株(菌数103個~104個)を内径15mmのpolypropylene製の容量15mlの試験管に入った10mlの培養液(食添培地)に接種し、37℃、19時間培養を行った。19時間の培養後、この内径15mmのpolypropylene製の容量15mlの試験管を、試験管内の液面以上となる十分な量の氷の中に試験管を挿入して(氷上)にて急速冷却し、氷上で5時間保持した後、急速冷却前(低温暴露前)の生菌数と氷上で5時間保持後(低温曝露後)の生菌数を比較し下記式で生菌率を評価する。
上記生菌数のカウント方法は、培養液をMRS寒天培地またはBCP加プレートカウント寒天培地に塗抹し、37℃微好気で48時間培養を行い、コロニーをカウントし生菌数を測定し評価した。
<低温耐性株の製造方法>
なお、低温耐性株の製造方法としては、例えば、CP2305株は10℃以下で生存率が低くなる傾向を示す。このため、低温耐性株の製造方法としては、対象株を、培養液(例:食添培地)にて適度な培養温度(例:37℃程度)で程度な培養時間(例:19時間程度)培養し、その後、培養液を10℃以下、好ましくは7℃以下、より好ましくは5℃以下、さらに好ましくは3℃以下、2℃以下、1℃以下の温度に適度な時間(例:5時間)曝露して、また、必要に応じ、これらの培養、低温曝露を繰り返すことによって、目的とする温度である低温に耐性がある株を製造する。
SD雄ラット(4週齢、日本チャールス・リバー社製)を12時間毎の明暗周期下(8時より12時間点灯)で1週間飼育後、試験菌体配合餌を以下のように3週間自由摂取させた。
(d)各回の糞便重量(i値)×各回の糞便スコア(ii値)を求める。
上記実験および定義された下痢スコアに基づいて、下記の効果を確認した。
比較対象とした寄託菌株A菌体(L. gassei)の結果は、CP2305株と同菌数投与した結果である。また、市販生菌製剤B(L. acidphilus)の結果は、ヒト1日分の摂取用量の重量をラットの体重換算で、単位体重あたり同量となるよう投与した結果である(図6)。本結果から従来下痢抑制作用があるとされている市販生菌剤などよりストレス性下痢を抑制する作用がCP2305株であることが証明され、CP2305s株もCP2305株と同様のストレス性下痢の抑制効果があることからCP2305s株の優位性が証明された。
さらにまた、CRF投与4時間後に解剖を実施し、結腸組織をISOGEN(ニッポンジーン)およびRNeasy Mini Kit(Qiagen,USA)にて総RNAを抽出後、遺伝子発現をRat whole genome ver. 3 (G4847B,Agilent,USA)で網羅的に解析を行った。その結果、プラセボ群でCRF投与後に増加するクロライド・チャネル関連遺伝子を、CP2305株投与群では抑制することを確認した(図3)。従って、CP2305株はクロライドチャネルを抑制し、水分の移動を制御していると考えられ、また、同様の下痢抑制効果を有するCP2305s株もクロライドチャネルを抑制し、水分の移動を制御していると考えられる。
SD系雄ラット(4週齢、株式会社紀和動物製)を12時間毎の明暗周期下(8時より12時間点灯)で1週間飼育後、CP2305株配合餌もしくは未配合対照粉餌を3週間自由摂食させた。実験当日はラットを3時間絶食させた後、ウレタン麻酔し、頚静脈に静脈投与用のカニューレを挿入し、その後、下部大腸を神経支配する骨盤(副交感)神経を銀電極で吊上げ、その電気活動を測定した。測定値が安定した時期にCRF溶液(1μg/kg)を頚静脈投与し骨盤神経の電気活動(PNA)の変化を電気生理学的に測定した。データは5分間毎の5秒あたりの発火頻度の平均値にて解析し、頚静脈投与直前の値(0分値)を100%として百分率で示した。その結果、ストレスホルモン(CRF)投与することで、ラット大腸を神経支配する骨盤(副交感)神経活動が抑制されることを確認した。更にはCP2305株の投与がストレス誘発の骨盤(副交感)神経抑制を阻害することを確認した(図4)。従って、CP2305株の投与により、ストレス時の腸管機能が正常に保たれるものと考えられ、また、同様の下痢抑制効果を有するCP2305s株も同様の効果があると考えられる。
SDラット(体重380~400g、日本SLC社製)を麻酔後、断頭、放血屠殺し、解剖学的基準により遠位結腸(distal colon)摘出し、実態顕微鏡下で輪走筋および縦走筋層を剥離し、粘膜下神経叢を含む粘膜-粘膜下神経叢標本を作製した。標本を測定面積0.64cm2のUssing chamber(CHM2, WPI, FL, USA)に装着し、標本の粘膜側-漿膜側間に生じる電位差及び短絡電流short-circuit current(ISC)を測定した。1分間に3秒間10mVのコマンドパルスを組織に与え、短絡電流の変化量から膜コンダクタンス(Gt)を算出した。basel ISC およびGtが安定したところで粘膜下神経に電気刺激(25V, duration of 0.5ms, 5Hz, 120s)を行い組織の状態を確認した。その後、試験乳酸菌の菌体または発酵乳の希釈溶液(500μg/ml)を粘膜側に投与し、ISCおよびGtの変化を測定し、神経刺激誘発により発生するCl-/HCO3 -分泌に対する試験物質の影響を評価した。
さらに、ラット大腸(遠位結腸)の神経刺激誘発のイオン輸送に及ぼす菌体のみの影響を評価するために、各種乳酸菌の殺菌体を調製し、投与した結果、CP2305株殺菌体は、公知寄託菌株A(L. gasseri)殺菌体及びL. acidophilus殺菌体と比較し、有意にイオン分泌を顕著に抑制し、下痢抑制に強く寄与していることが示唆された(図8)。
Claims (34)
- ラクトバチルス・ガセリCP2305s株(NITE BP-1405)、又はラクトバチルス・ガセリCP2305株(FERM BP-11331)もしくはCP2305s株(NITE BP-1405)から派生した派生株、それらの菌体処理物、或いはそれらの混合物、を有効成分として含有することを特徴とする、腸管での水分過剰分泌、ストレス性下痢、ストレス性腸障害、過敏性腸症候群、又は炎症性腸疾患の軽減剤。
- ラクトバチルス・ガセリCP2305株(FERM BP-11331)、その菌体処理物、或いはそれらの混合物、を有効成分として含有することを特徴とする、腸管での水分過剰分泌、又はストレス性下痢の軽減剤。
- ラクトバチルス・ガセリCP2305株(FERM BP-11331)の殺菌体、その菌体処理物、或いはそれらの混合物、を有効成分として含有することを特徴とする、腸管での水分過剰分泌、ストレス性下痢、又はストレス性腸障害の軽減剤。
- 前記CP2305株、前記CP2305s株、又はラクトバチルス・ガセリCP2305株(FERM BP-11331)もしくはCP2305s株(NITE BP-1405)から派生した派生株が、生菌体又は殺菌体である、請求項1又は2に記載の軽減剤。
- 前記菌体処理物が、乾燥菌体、破壊菌体、破砕菌体又は発酵乳である、請求項1~4のいずれか1項に記載の軽減剤。
- ストレスによる骨盤(副交感)神経活動の抑制を阻害する作用を有する、請求項1~5のいずれか1項に記載の軽減剤。
- 大腸クロライドチャネルを抑制することによって水分分泌を抑制する作用を有する、請求項1~6のいずれか1項に記載の軽減剤。
- ストレス性下痢の改善剤である、請求項1~7のいずれか1項に記載の軽減剤。
- 請求項1~8のいずれか1項に記載の軽減剤を動物飼料成分と配合して動物飼料を製造する工程を含む、動物飼料の製造方法。
- ラクトバチルス・ガセリCP2305s株(NITE BP-1405)、又はラクトバチルス・ガセリCP2305株(FERM BP-11331)もしくはCP2305s株(NITE BP-1405)から派生した派生株、の生菌体又は殺菌体、それらの菌体処理物、或いはそれらの混合物、を含有する動物飼料。
- 請求項1~10のいずれか1項に記載の軽減剤を含有する食品添加剤又は動物飼料添加剤。
- ラクトバチルス・ガセリCP2305株(FERM BP-11331)、ラクトバチルス・ガセリCP2305s株(NITE BP-1405)、又はラクトバチルス・ガセリCP2305株(FERM BP-11331)もしくはCP2305s株から派生した派生株、の生菌体又は殺菌体、それらの菌体処理物、或いはそれらの混合物、を含有する食品添加物。
- ラクトバチルス・ガセリCP2305s株(NITE BP-1405)、又はラクトバチルス・ガセリCP2305株(FERM BP-11331)もしくはCP2305s株から派生した派生株、の生菌体又は殺菌体、それらの菌体処理物、或いはそれらの混合物、を含有する飲食品。
- 機能性飲食品である、請求項13に記載の飲食品。
- 請求項1~8のいずれか1項に記載の軽減剤を食品用の担体、賦形剤又は希釈剤と混合し、場合により食品添加剤をさらに混合して、機能性飲食品を製造することを含む、機能性飲食品の製造方法。
- ラクトバチルス・ガセリCP2305s株(NITE BP-1405)、又はラクトバチルス・ガセリCP2305株(FERM BP-11331)もしくはCP2305s株から派生した派生株、の生菌体又は殺菌体、それらの菌体処理物、或いはそれらの混合物、を有効成分として含有することを特徴とする、腸管での水分過剰分泌、ストレス性下痢、ストレス性腸障害、過敏性腸症候群、又は炎症性腸疾患の予防、軽減若しくは抑制、又は治療するための医薬組成物。
- ラクトバチルス・ガセリCP2305株(FERM BP-11331)、その菌体処理物、或いはそれらの混合物、を有効成分として含有することを特徴とする、腸管での水分過剰分泌、又はストレス性下痢の予防、軽減若しくは抑制、又は治療するための医薬組成物。
- ラクトバチルス・ガセリCP2305株(FERM BP-11331)の殺菌体、その菌体処理物、或いはそれらの混合物、を有効成分として含有することを特徴とする、腸管での水分過剰分泌、ストレス性下痢、ストレス性腸障害の予防、軽減若しくは抑制、又は治療するための医薬組成物。
- 請求項1~8のいずれか1項に記載の軽減剤と、薬学的に許容されうる担体、賦形剤又は希釈剤とを含む、腸管での水分過剰分泌、ストレス性下痢、ストレス性腸障害、過敏性腸症候群、又は炎症性腸疾患を予防、軽減若しくは抑制、又は治療するための医薬組成物。
- ラクトバチルス・ガセリCP2305株(FERM BP-11331)又はラクトバチルス・ガセリCP2305s株(NITE BP-1405)と同等以上のストレス性腸障害の軽減作用を有し、かつCP2305株と異なる乳酸菌。
- 前記ストレス性腸障害の軽減作用が、明細書の実施例3記載の下痢スコアでラクトバチルス・ガセリCP2305株(FERM BP-11331)又はラクトバチルス・ガセリCP2305s株(NITE BP-1405)と同等以上のストレス性下痢抑制作用を有する、請求項20に記載の乳酸菌。
- 明細書の実施例3記載の方法によって下痢スコアを評価した場合においてプラセボと比較して有意(p<0.05vsプラセボ)にストレス性下痢を抑制しかつCP2305株(FERM BP-11331)と異なる乳酸菌。
- 氷上で5時間保持したときの生存率が、60%以上である低温耐性を有する、請求項20~22のいずれか1項に記載の乳酸菌。
- ストレスによる骨盤(副交感)神経活動の抑制を阻害する作用を有する、請求項20~23のいずれか1項に記載の乳酸菌。
- 大腸クロライドチャネルを抑制することによって水分分泌を抑制する作用を有する、請求項19~24のいずれか1項に記載の乳酸菌。
- 上記乳酸菌がラクトバチルス・ガセリ種に属する乳酸菌であることを特徴とする、請求項20~25のいずれか1項に記載の乳酸菌。
- 上記乳酸菌がラクトバチルス・ガセリCP2305s株(NITE BP-1405)、ラクトバチルス・ガセリCP2305株(FERM BP-11331)の派生株又はラクトバチルス・ガセリCP2305s株(NITE BP-1405)の派生株である、請求項20~26のいずれか1項に記載の乳酸菌。
- 腸管での水分過剰分泌、ストレス性下痢、ストレス性腸障害、過敏性腸症候群、下痢型過敏性腸症候群、又は炎症性腸疾患の予防又は軽減に用いるためのものである、請求項20~27のいずれか1項に記載の乳酸菌。
- 乳酸菌を10℃以下の温度に曝露し、生存した低温耐性株を選抜し、育種すること、必要に応じてこの操作を繰り返すこと、及び生存した低温耐性株を回収することを含む、乳酸菌低温耐性株の製造方法。
- 乳酸菌がラクトバチルス・ガセリ種に属する乳酸菌、又はラクトバチルス・ガセリCP2305株(FERM BP-11331)である、請求項29に記載の方法。
- ラクトバチルス・ガセリCP2305s株(NITE BP-1405)、又はラクトバチルス・ガセリCP2305株(FERM BP-11331)もしくはCP2305s株から派生した派生株からなる乳酸菌。
- 氷上で5時間保持したときの生存率が、60%以上である低温耐性を有する、乳酸菌。
- 上記乳酸菌がラクトバチルス・ガセリ種に属する乳酸菌であることを特徴とする、請求項32記載の乳酸菌。
- 請求項20~27及び31~33のいずれか1項に記載の乳酸菌を有効成分として含有することを特徴とする、腸管での水分過剰分泌、ストレス性下痢、ストレス性腸障害、過敏性腸症候群、下痢型過敏性腸症候群、又は炎症性腸疾患の予防又は軽減剤。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380059938.4A CN104797265A (zh) | 2012-11-16 | 2013-11-15 | 含有特定的加氏乳杆菌株或其处理物的压力性肠紊乱的减轻剂 |
US14/443,089 US20150283187A1 (en) | 2012-11-16 | 2013-11-15 | Agent for alleviating stress-induced bowel disorder containing specific lactobacillus gasseri strain or treated product thereof |
EP13854909.2A EP2923704B1 (en) | 2012-11-16 | 2013-11-15 | Stress-induced bowel disorder-relieving agent comprising specific lactobacillus gasseri strain or treatment product thereof |
CA2890507A CA2890507A1 (en) | 2012-11-16 | 2013-11-15 | Agent for alleviating stress-induced bowel disorder containing specific lactobacillus gasseri strain or treated product threof |
BR112015010978A BR112015010978A2 (pt) | 2012-11-16 | 2013-11-15 | agente para alívio de distúrbio intestinal induzido por estresse contendo cepa de lactobacillus gasseri específica ou produto tratado da mesma |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012252642 | 2012-11-16 | ||
JP2012252527A JP2014101288A (ja) | 2012-11-16 | 2012-11-16 | ストレス性腸障害の抑制剤 |
JP2012-252422 | 2012-11-16 | ||
JP2012-252527 | 2012-11-16 | ||
JP2012-252642 | 2012-11-16 | ||
JP2012252422A JP6053466B2 (ja) | 2012-11-16 | 2012-11-16 | ストレス性下痢の抑制剤 |
JP2013-009332 | 2013-01-22 | ||
JP2013009332A JP6214162B2 (ja) | 2012-11-16 | 2013-01-22 | 新規の低温耐性ラクトバチルス・ガセリ株 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014077365A1 true WO2014077365A1 (ja) | 2014-05-22 |
Family
ID=53178089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/080930 WO2014077365A1 (ja) | 2012-11-16 | 2013-11-15 | 特定のラクトバチルス・ガセリ株又はその処理物を含有するストレス性腸障害の軽減剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20150283187A1 (ja) |
EP (1) | EP2923704B1 (ja) |
CN (1) | CN104797265A (ja) |
BR (1) | BR112015010978A2 (ja) |
CA (1) | CA2890507A1 (ja) |
WO (1) | WO2014077365A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017221799A1 (ja) * | 2016-06-20 | 2017-12-28 | 株式会社明治 | 上部消化管内菌叢改善剤 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140322172A1 (en) | 2011-12-07 | 2014-10-30 | Calpis Co., Ltd. | Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof |
JP6894096B2 (ja) * | 2016-06-30 | 2021-06-23 | アサヒグループホールディングス株式会社 | 軟骨再生促進用組成物 |
AU2017287988A1 (en) * | 2016-06-30 | 2019-02-21 | Asahi Group Holdings, Ltd. | Renal anemia ameliorating composition |
JP6990660B2 (ja) | 2016-10-20 | 2022-01-12 | ビオフェルミン製薬株式会社 | 腸管のイオン経細胞輸送体への作用剤、クロライドチャネル活性化剤、腎疾患の予防もしくは治療剤、又は排便促進剤 |
US20190193928A1 (en) * | 2017-12-21 | 2019-06-27 | Pepsico, Inc. | Multi-ingredient ephemeral beverage pod for making a beverage |
JPWO2021015104A1 (ja) * | 2019-07-24 | 2021-01-28 | ||
CN113234644B (zh) * | 2021-06-30 | 2022-08-23 | 江南大学 | 一株可缓解etec致腹泻的格氏乳杆菌及其应用 |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003095963A (ja) | 2001-09-20 | 2003-04-03 | Snow Brand Milk Prod Co Ltd | 炎症性腸疾患及び過敏性腸症候群の予防・治療剤 |
JP2004305128A (ja) | 2003-04-08 | 2004-11-04 | Meiji Shiryo Kk | 飼料組成物 |
JP2005536197A (ja) * | 2002-06-28 | 2005-12-02 | プレバ、バイオテック、ソシエダッド、アノニマ | プロバイオティクス菌株、その選択方法、その組成物、およびその使用 |
JP2008212140A (ja) | 2007-02-09 | 2008-09-18 | Crossfield Bio Inc | 新規なラクトバチルス属微生物および乳酸菌製剤 |
JP2009511471A (ja) | 2005-10-06 | 2009-03-19 | プロビ エービー | 自己免疫疾患治療のための乳酸菌の使用 |
JP2009100692A (ja) | 2007-10-24 | 2009-05-14 | Crossfield Bio Inc | 新規なラクトバチルス属微生物および哺乳動物用乳酸菌製剤 |
JP2009102292A (ja) | 2007-04-27 | 2009-05-14 | Chiba Prefecture | ストレス抑制剤 |
JP4350170B2 (ja) | 1997-06-02 | 2009-10-21 | エスーム、アクチボラグ | ラクトバチルス・カセイ・ラムノススを含む薬学的調製物 |
JP2011135804A (ja) * | 2009-12-28 | 2011-07-14 | Meiji Co Ltd | 酸素耐性が増強された微生物およびその利用 |
JP2011200211A (ja) | 2010-03-26 | 2011-10-13 | Morinaga Milk Ind Co Ltd | 新規乳酸菌、並びに新規乳酸菌を含有する医薬、飲食品、及び飼料 |
JP2012017282A (ja) * | 2010-07-07 | 2012-01-26 | Calpis Co Ltd | 迷走神経活性化剤 |
WO2012105312A1 (ja) * | 2011-02-02 | 2012-08-09 | カルピス株式会社 | 関節炎予防改善用物質 |
JP2012188409A (ja) * | 2011-03-14 | 2012-10-04 | Biofuerumin Seiyaku Kk | 消化管痛の予防又は軽減剤 |
WO2013084971A1 (ja) * | 2011-12-07 | 2013-06-13 | カルピス株式会社 | 乳酸菌又はその処理物を含む脂質代謝及び/又は糖代謝改善剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BG110506A (bg) * | 2009-10-27 | 2011-05-31 | "Селур Вк Холдинг" Еоод | Нови щамове млечно-кисели бактерии и техни комбинации за получаване на пробиотични препарати |
-
2013
- 2013-11-15 CN CN201380059938.4A patent/CN104797265A/zh active Pending
- 2013-11-15 EP EP13854909.2A patent/EP2923704B1/en active Active
- 2013-11-15 WO PCT/JP2013/080930 patent/WO2014077365A1/ja active Application Filing
- 2013-11-15 BR BR112015010978A patent/BR112015010978A2/pt not_active Application Discontinuation
- 2013-11-15 CA CA2890507A patent/CA2890507A1/en not_active Abandoned
- 2013-11-15 US US14/443,089 patent/US20150283187A1/en not_active Abandoned
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4350170B2 (ja) | 1997-06-02 | 2009-10-21 | エスーム、アクチボラグ | ラクトバチルス・カセイ・ラムノススを含む薬学的調製物 |
JP4853986B2 (ja) | 2001-09-20 | 2012-01-11 | 雪印メグミルク株式会社 | 炎症性腸疾患及び過敏性腸症候群の予防・治療剤 |
JP2003095963A (ja) | 2001-09-20 | 2003-04-03 | Snow Brand Milk Prod Co Ltd | 炎症性腸疾患及び過敏性腸症候群の予防・治療剤 |
JP2005536197A (ja) * | 2002-06-28 | 2005-12-02 | プレバ、バイオテック、ソシエダッド、アノニマ | プロバイオティクス菌株、その選択方法、その組成物、およびその使用 |
JP2004305128A (ja) | 2003-04-08 | 2004-11-04 | Meiji Shiryo Kk | 飼料組成物 |
JP2009511471A (ja) | 2005-10-06 | 2009-03-19 | プロビ エービー | 自己免疫疾患治療のための乳酸菌の使用 |
JP2008212140A (ja) | 2007-02-09 | 2008-09-18 | Crossfield Bio Inc | 新規なラクトバチルス属微生物および乳酸菌製剤 |
JP2009102292A (ja) | 2007-04-27 | 2009-05-14 | Chiba Prefecture | ストレス抑制剤 |
JP2009100692A (ja) | 2007-10-24 | 2009-05-14 | Crossfield Bio Inc | 新規なラクトバチルス属微生物および哺乳動物用乳酸菌製剤 |
JP2011135804A (ja) * | 2009-12-28 | 2011-07-14 | Meiji Co Ltd | 酸素耐性が増強された微生物およびその利用 |
JP2011200211A (ja) | 2010-03-26 | 2011-10-13 | Morinaga Milk Ind Co Ltd | 新規乳酸菌、並びに新規乳酸菌を含有する医薬、飲食品、及び飼料 |
JP2012017282A (ja) * | 2010-07-07 | 2012-01-26 | Calpis Co Ltd | 迷走神経活性化剤 |
WO2012105312A1 (ja) * | 2011-02-02 | 2012-08-09 | カルピス株式会社 | 関節炎予防改善用物質 |
JP2012158568A (ja) * | 2011-02-02 | 2012-08-23 | Calpis Co Ltd | 関節炎予防改善用物質 |
JP2012188409A (ja) * | 2011-03-14 | 2012-10-04 | Biofuerumin Seiyaku Kk | 消化管痛の予防又は軽減剤 |
WO2013084971A1 (ja) * | 2011-12-07 | 2013-06-13 | カルピス株式会社 | 乳酸菌又はその処理物を含む脂質代謝及び/又は糖代謝改善剤 |
Non-Patent Citations (5)
Title |
---|
DAISUKE SAWADA ET AL., 13TH ANNUAL MEETING OF INTESTINAL MICROBIOLOGY, 2009 |
DAISUKE SAWADA ET AL.: "10th Symposium on Lactic Acid Bacteria", 2011, FEDERATION OF EUROPEAN MICROBIOLOGICAL SOCIETIES (FEMS |
DAISUKE SAWADA ET AL: "CONTINUOUS ORAL INTAKE OF FERMENTED MILK PRODUCT WITH LACTOBACILLUS GASSERI STRAIN CP 2305:A POTENTIAL AND PRACTICAL APPROACH TO STRESS PROTECTION", JOURNAL OF INTESTINAL MICROBIOLOGY, vol. 23, no. 2, 2009, pages 96, XP008174116 * |
DAISUKE SAWADA ET AL: "EFFECT OF LACTOBACILLUS GASSERI STRAIN CP2305 ON SYMPOMS OF CRF-INDUCED DIARRHEA AND STUDY ON ITS WORKING MECHANISM", JOURNAL OF INTESTINAL MICROBIOLOGY, vol. 27, no. 2, April 2013 (2013-04-01), pages 119, XP008179970 * |
See also references of EP2923704A4 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017221799A1 (ja) * | 2016-06-20 | 2017-12-28 | 株式会社明治 | 上部消化管内菌叢改善剤 |
JPWO2017221799A1 (ja) * | 2016-06-20 | 2019-04-11 | 株式会社明治 | 上部消化管内菌叢改善剤 |
JP7101354B2 (ja) | 2016-06-20 | 2022-07-15 | 株式会社明治 | 上部消化管内菌叢改善剤 |
Also Published As
Publication number | Publication date |
---|---|
EP2923704A1 (en) | 2015-09-30 |
US20150283187A1 (en) | 2015-10-08 |
BR112015010978A2 (pt) | 2017-07-11 |
CA2890507A1 (en) | 2014-05-22 |
EP2923704A4 (en) | 2016-12-07 |
EP2923704B1 (en) | 2024-03-20 |
CN104797265A (zh) | 2015-07-22 |
EP2923704C0 (en) | 2024-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014077365A1 (ja) | 特定のラクトバチルス・ガセリ株又はその処理物を含有するストレス性腸障害の軽減剤 | |
AU2016324846B2 (en) | Novel lactobacillus and composition for preventing, improving, or treating degenerative brain diseases or cognitive function disorders | |
KR101683474B1 (ko) | 과민성 대장 증후군 예방 또는 치료용 조성물 | |
KR101473058B1 (ko) | 과민성 대장 증후군 예방 또는 치료용 조성물 | |
CN102458426B (zh) | 产生细菌素的戊糖乳杆菌及其在食品和药物组合物中的应用 | |
Mohankumar et al. | Characterization and antibacterial activity of bacteriocin producing Lactobacillus isolated from raw cattle milk sample | |
JP6837015B2 (ja) | たとえば、細菌性膣炎の治療のためのLactobacillus rhamnosus(ラクトバチルス・ラムノサス)細菌 | |
KR101618391B1 (ko) | 높은 옥살산 분해능을 갖는 유산균 | |
KR101228035B1 (ko) | 신규한 유산균 및 이를 포함하는 당뇨병 예방 및 치료용 조성물 | |
JP6214162B2 (ja) | 新規の低温耐性ラクトバチルス・ガセリ株 | |
EP3808357A1 (en) | Composition and uses thereof | |
KR101656208B1 (ko) | 염증 질환 예방 또는 치료용 조성물 | |
US11058733B2 (en) | Active substances of Bifidobacterium lactis GKK2, composition comprising the same and method of promoting longevity using the same | |
JP2023033532A (ja) | 骨格筋遅筋化用組成物 | |
CN114262678B (zh) | 一种发酵乳杆菌Pm007及其应用 | |
JP6053466B2 (ja) | ストレス性下痢の抑制剤 | |
JP2014101288A (ja) | ストレス性腸障害の抑制剤 | |
KR101453982B1 (ko) | 과민성 대장 증후군 예방 또는 치료용 조성물 | |
Koščová et al. | Effect of two plant extracts and Lactobacillus fermentum on colonization of gastrointestinal tract by Salmonella enterica var. Düsseldorf in chicks | |
JP2009100692A (ja) | 新規なラクトバチルス属微生物および哺乳動物用乳酸菌製剤 | |
KR20210067860A (ko) | 혈중 암모니아 수치 저하능을 갖는 균주 및 이를 포함하는 신경세포 보호용 조성물 | |
KR102577986B1 (ko) | 혈중 암모니아 수치 저하능을 갖는 균주 및 이를 포함하는 신경세포 보호용 조성물 | |
KR101453984B1 (ko) | 과민성 대장 증후군 예방 또는 치료용 조성물 | |
Ramadan et al. | Potential in vitro anti-helicobacter activity of bacteriocin and bacteriocin-like compounds produced by lactobacilli | |
Guo et al. | Comparative evaluation of three Lactobacilli with strain-specific activities for rats when supplied in drinking water |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13854909 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2890507 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14443089 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015010978 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013854909 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112015010978 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150513 |